Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
2
50%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin

NCT07124819
completed

Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study

NCT07134738
completedphase_3

Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

NCT05185804
completedphase_1

A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217)

NCT05181241

Clinical Trials (4)

Showing 4 of 4 trials
NCT07124819Phase 3

Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin

Completed
NCT07134738

Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study

Completed
NCT05185804Phase 3

Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

Completed
NCT05181241Phase 1

A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4